The Portfolio returned 7.33% gross, significantly outperforming the MSCI World Health Care Index's 3.12% return. Click here ...

REGAL is a Phase 3 randomized study testing GPS in AML patients who reached complete remission after a second round of rescue ...

For a stock that had been struggling for significance for much of the past year, this dramatic shift was not merely a rally — ...

Discover why Wave Life Sciences Ltd. is a high-risk, high-reward biotech with unique RNA therapies for AATD, obesity, and more. Click for this WVE stock update.

We recently compiled a list of the 7 Most Promising Gene Editing Stocks According to Analysts. Wave Life Sciences Ltd. tops ...

Through the first three quarters of 2025, M&A activity overtook the entire 2024 total, according to Endpoints News. Editor and founder John Carroll wrote in October this might be the best time in 15 ...

Wave's bullish start to the week was driven by the encouraging readout of a Phase 1 clinical study of WVE-007, its obesity ...

Life Sciences ventures face high levels of scientific, clinical and commercial pathway uncertainty, and these uncertainties present many opportunities for entrepreneurial innovation. This course is ...

Salesforce (NYSE: CRM), the world’s #1 AI CRM, announced today that Novartis (NYSE: NVS), a leading global innovative ...

The Board on Life Sciences (BLS) was established in 1984 to serve as the focal point for addressing critical, emerging policy and technical issues associated with the life sciences and biotechnology ...

The developer behind Philadelphia's largest life sciences building says the market needs patience after venture capital ...

William “Bill” McKeon is the President and Chief Executive Officer of the Texas Medical Center. He is responsible for driving strategic, operational and programmatic initiatives across the Texas ...